My MS Toolkit: a Symptom Self-management Program for Multiple Sclerosis

Overview

My MS Toolkit is a web-based symptom self-management program for persons with multiple sclerosis. This study is evaluating various aspects of My MS Toolkit and how it impacts symptom self-management in multiple sclerosis. The research team believe that the toolkit will be feasible, acceptable, and beneficial to participants.

Full Title of Study: “Testing a New Multiple Sclerosis Specific Web-based Symptom Self-management Program: My MS Toolkit”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Health Services Research
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 25, 2019

Detailed Description

Study participants will be asked to use a newly developed web-based symptom self-management program, called the My MS Toolkit, for 12 weeks. Participants will also be asked to complete online surveys throughout the study. The My MS Toolkit includes 8 modules that describe symptom self-management strategies. Participants will explore the My MS Toolkit on their own, following the prompts and guides built into the program, and are encouraged to practice and apply the skills learned. The study can be done from participants' homes using a reliable internet-connected device. No travel is required.

Interventions

  • Other: My MS Toolkit
    • My MS Toolkit, a web-based self-management intervention designed to help persons with Multiple Sclerosis self-manage fatigue, pain, and depressed mood.

Arms, Groups and Cohorts

  • Experimental: My MS Toolkit
    • 20 Participants asked to use My MS Toolkit.

Clinical Trial Outcome Measures

Primary Measures

  • Acceptability of My MS Toolkit
    • Time Frame: week 12-week 14
    • Assessed by the Patient Satisfaction Evaluation Scale, 12 question scale where each response score ranges from 4 to 1 and the total score ranges from 48 to 12. Higher scores indicate increased satisfaction.
  • Feasibility of My MS Toolkit
    • Time Frame: up to week 12
    • Assessed by the treatment adherence questionnaire that consists of 5 questions that assess: 1) how many times the participant accessed the website in the prior two weeks; 2) how many minutes the participant spent on the website; 3) which parts of the website the participant accessed; 4) which activities the participant engaged in; and 5) which skill from the website the participant used. The items on this questionnaire will be used to describe the use of the website for assessing treatment adherence by participants in the study.

Secondary Measures

  • Impact of My MS Toolkit: Change in fatigue
    • Time Frame: Pre- and post-treatment, up to 14 weeks
    • The Modified Fatigue Impact Scale will be used to assess fatigue. It is a self-report survey that contains 21 items. Each item is rated 0-4. Higher scores indicate a greater impact of fatigue on a person’s activities.
  • Impact My MS Toolkit: Change in pain interference
    • Time Frame: up to 14 weeks
    • The BPI-SF is a 9-item questionnaire (15 prompts) with two domains: pain severity and pain interference. The 7 pain interference items have values which range from 0 (“does not interfere”) to 10 (“completely interferes”); items are averaged for a scale score range of 0-10, with higher scores indicating more pain interference.
  • Impact My MS Toolkit: Change in depressive symptoms
    • Time Frame: up to 14 weeks
    • The eight-item Patient Health Questionnaire depression scale (PHQ-8) is established as a valid diagnostic and severity measure for depressive disorders in large clinical studies. Scores range from 0 – 24 and a score of 10 or greater is consistent with at least moderate depressive symptoms.
  • Change in self-efficacy for managing symptoms
    • Time Frame: up to 14 weeks
    • Changes measured by the University of Washington Self-Efficacy Scale (UW-SES), higher score indicates higher levels of self-efficacy (total score range: 6-30)
  • Participant perception of change
    • Time Frame: week 12-14
    • Perception of change is assessed by the patient global impression of change questionnaire, which is 1 question and responses range from 1-7. Higher numbers indicate greater improvement in condition.

Participating in This Clinical Trial

Inclusion Criteria

  • Multiple Sclerosis – Have access to a reliable, internet-connected device (e.g. computer, tablet). (Note: this study is conducted electronically and is not location dependent.) – One or more of the following: 1. Moderate/moderately severe depressive symptoms 2. Chronic pain 3. Presence of significant fatigue symptoms – Read, speak and understand English. Exclusion Criteria:

  • Significant cognitive impairment – Current psychotherapy for symptoms

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Michigan
  • Collaborator
    • United States Department of Defense
  • Provider of Information About this Clinical Study
    • Principal Investigator: Anna Kratz, Associate Professor of Physical Medicine and Rehabilitation – University of Michigan
  • Overall Official(s)
    • Anna Kratz, Principal Investigator, University of Michigan

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.